Sonnet Biotherapeutics Net Worth
Sonnet Biotherapeutics Net Worth Breakdown | SONN |
Sonnet Biotherapeutics Net Worth Analysis
Sonnet Biotherapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sonnet Biotherapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sonnet Biotherapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sonnet Biotherapeutics' net worth analysis. One common approach is to calculate Sonnet Biotherapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sonnet Biotherapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sonnet Biotherapeutics' net worth. This approach calculates the present value of Sonnet Biotherapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sonnet Biotherapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sonnet Biotherapeutics' net worth. This involves comparing Sonnet Biotherapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sonnet Biotherapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Sonnet Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sonnet Biotherapeutics' net worth research are outlined below:
| Sonnet Biotherapeutics generated a negative expected return over the last 90 days | |
| Sonnet Biotherapeutics has high historical volatility and very poor performance | |
| Sonnet Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 147.81 K. Net Loss for the year was (18.83 M) with loss before overhead, payroll, taxes, and interest of (21.09 M). | |
| Sonnet Biotherapeutics Holdings currently holds about 5.22 M in cash with (21.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.21. | |
| Sonnet Biotherapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Sonnet BioTherapeutics Releases Virtual Investor What this Means Segment |
Sonnet Biotherapeutics Quarterly Good Will |
|
Sonnet Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sonnet Biotherapeutics Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sonnet Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Know Sonnet Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sonnet Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sonnet Biotherapeutics Holdings backward and forwards among themselves. Sonnet Biotherapeutics' institutional investor refers to the entity that pools money to purchase Sonnet Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | Private Wealth Management Group Llc | 2024-09-30 | 0.0 | Sabby Management Llc | 2024-06-30 | 238.4 K | Virtu Financial Llc | 2024-06-30 | 32.7 K | Tower Research Capital Llc | 2024-06-30 | 7.2 K | Ubs Group Ag | 2024-06-30 | 4 K | Blackrock Inc | 2024-06-30 | 520 | Bank Of America Corp | 2024-06-30 | 28.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 4.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 |
Follow Sonnet Biotherapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.5 M.Market Cap |
|
Project Sonnet Biotherapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.63) | (1.72) | |
| Return On Capital Employed | (0.18) | (0.17) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.92) | (0.88) |
When accessing Sonnet Biotherapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sonnet Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sonnet Biotherapeutics' profitability and make more informed investment decisions.
Evaluate Sonnet Biotherapeutics' management efficiency
Sonnet Biotherapeutics has return on total asset (ROA) of (0.9693) % which means that it has lost $0.9693 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6457) %, meaning that it created substantial loss on money invested by shareholders. Sonnet Biotherapeutics' management efficiency ratios could be used to measure how well Sonnet Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to -1.72. In addition to that, Return On Capital Employed is likely to grow to -0.17. At this time, Sonnet Biotherapeutics' Other Assets are very stable compared to the past year. As of the 25th of November 2024, Net Tangible Assets is likely to grow to about 9 M, while Total Assets are likely to drop about 28.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 18.8 K | 34 K | |
| Tangible Book Value Per Share | -39.4 K | -37.5 K | |
| Enterprise Value Over EBITDA | (12.43) | (11.81) | |
| Price Book Value Ratio | 4.88 | 5.12 | |
| Enterprise Value Multiple | (12.43) | (11.81) | |
| Price Fair Value | 4.88 | 5.12 | |
| Enterprise Value | 46.1 M | 43.8 M |
Leadership effectiveness at Sonnet Biotherapeutics Holdings is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Enterprise Value Revenue 35.9059 | Revenue 55.9 K | Quarterly Revenue Growth (0.50) | Revenue Per Share 0.019 | Return On Equity (2.65) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sonnet Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sonnet Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sonnet Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sonnet Biotherapeutics Corporate Filings
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 7th of November 2024 Other Reports | ViewVerify | |
| 4th of November 2024 Other Reports | ViewVerify | |
S1 | 28th of October 2024 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Sonnet Biotherapeutics Earnings per Share Projection vs Actual
Sonnet Biotherapeutics Corporate Management
| Manuel Dafonseca | Head Operations | Profile | |
| Stephen McAndrew | Senior Development | Profile | |
| Gael Hedou | Chief Officer | Profile | |
| John Cini | Chief CoFounder | Profile | |
| MD FACP | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.